A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 70, Issue 3, 1998, Pages 334-338

  Look, Katherine Y ^a   Blessing, John A ^b   Levenback, Charles ^c   Kohler, Matthew ^d   Chafe, Weldon ^e   Roman, Lynda D ^f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CPT 11; Squamous carcinoma of the cervix

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MITOLACTOL; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDICATION; FEMALE; GASTROINTESTINAL TOXICITY; HEMATURIA; HUMAN; HYPOKALEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEUROTOXICITY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 0032168956     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5129     Document Type: Article

References (18)

1. Bonomi P, Blessing J A, Stehman F B, DiSaia P, Walton L, Major F. Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix - A Gynecologic Oncology Group study. J Clin Oncol. 3:1985;1079-1085.
2. Sutton G P, Blessing J B, McGuire W P, Patton T, Look K Y. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: A Gynecology Oncology Group study. Am J Obstet Gynecol. 168:1993;805-807.
3. Stehman F B, Blessing J A, McGehee R, McGehee R, Barrett R J. A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 7:1989;1892-1895.
4. McGuire W P, Blessing J A, Moore D, Lentz S S, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 14:1996;792-795.
5. Omura G A, Blessing J A, Vaccarello L, Berman M, Mutch D, Clarke-Pearson D, Anderson B. Randomized trial of cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 15:1997;165-171.
6. Hsiang Y H, Lihou M G, Liu L F. Arrest of replication forks by drug-stabilized topisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin analogues. Cancer Res. 49:1989;5077-5083.
7. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptotecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res. 51:1991;4187-4191.
8. Takeuchi S, Noda K, Yakushiju M. Late phase II study of CPT-11, a topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol. 11:1992;224.
9. Verschraegen C F, Levy T, Kudelka A P, Llerena E, Ende K, Freedman R S, Edwards C LS, Hord M, Steger M, Kaplan A L, Kieback D, Fishman A M, Kavanagh J J. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 15:1997;625-631.
10. Rothenberg M L, Kuhn J G, Burris H A, Nelson J, Eckardt J R, Tristan-Morales M, Hilsenbeck S G, Weiss G R, Smith L S, Rodriguez G I. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 11:1993;2194-2204.
11. Blessing J A. Design, Analysis and Interpretation of Chemotherapy Trials in Gynecologic Cancer. Chemotherapy of Gynecologic Cancer. 1990;A. R Liss, New York. p. 63-97.
12. Eckhardt J, Eckhardt G, Villalona-Calera M, Drengler F, Von Hoff D. New anticancer agents in clinical development. Oncology. 9:1995;1191-1199.
13. Ikuno N, Soda H, Wantanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal damages in the mouse ileum and cecum. J Natl Cancer Inst. 87:1995;1876-1883.
14. Mic R, Gupta E, Vokes E E, Ratain M J. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynacis: prediction of biliary index and intestinal toxicity. J Clin Oncol. 14:1996;2012-2019.
15. Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, Negoro S, Matsui K, Takifuji N, Morino H. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res. 84:1993;203-207.
16. Sugiyama T, Nishida T, Ushijima K, Kumagai S, Yskushiji M. Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or metastatic ovarian cancer. Proc Am Soc Clin Oncol. 15:1996;291.
17. Ueoka, H, Tabata, M, Shibayama, T, Kiura, K, Harada, M, Segawa, Y, Satoh, T, Hiraki, S, Ohnoshi, T, A phase I study of irinotecan (CPT-11) and cisplatin (CDDP) in advanced lung cancer (ED-SCLC and IIIB/IV-NSCLC), Proc Am Soc Clin Oncol, 15, 385, 1996, 1154.
18. Kobayashi K, Soma T, Shinbara A, Kudoh K, Kabe J, Hino M, Shibuya M, Kudoh S. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) by divided administration in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 15:1996;388.